1. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.
- Author
-
Hamaguchi T, Tsuji A, Yamaguchi K, Takeda K, Uetake H, Esaki T, Amagai K, Sakai D, Baba H, Kimura M, Matsumura Y, and Tsukamoto T
- Subjects
- Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Drug Carriers chemistry, Female, Glucuronosyltransferase genetics, Humans, Infusions, Intravenous, Irinotecan administration & dosage, Irinotecan pharmacokinetics, Kaplan-Meier Estimate, Male, Micelles, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Polymers chemistry, Polymorphism, Genetic, Progression-Free Survival, Topoisomerase I Inhibitors administration & dosage, Topoisomerase I Inhibitors pharmacokinetics, Colorectal Neoplasms drug therapy, Irinotecan therapeutic use, Neoplasm Recurrence, Local drug therapy, Topoisomerase I Inhibitors therapeutic use
- Abstract
Purpose: NK012 is a polymeric micelle formulation of SN-38, the active metabolite of irinotecan. We evaluated the efficacy and safety of NK012 in Japanese patients with unresectable metastatic colorectal cancer., Methods: We conducted a multicenter open-label phase II trial of NK012 monotherapy in 58 patients who had been treated with an oxaliplatin-based chemotherapy regimen (group A: 53 patients with UGT1A1 genotype -/-, *6/-, or *28/-; group B: 5 patients with UGT1A1 genotype *6/*28 or *6/*6). The primary endpoint was the response rate (RR). Initial doses of 28 and 18 mg/m
2 for group A and group B, respectively, were administered intravenously over 30 min, and these doses were subsequently administered every 3 weeks. Group A was evaluated as the primary efficacy population, while group B was evaluated for reference., Results: In group A, the RR was 3.8%, and the median progression-free survival and overall survival were 3.30 months and 15.03 months, respectively. In both groups, the most common grade ≥ 3 adverse drug reaction (ADR) was neutropenia and the incidence of grade ≥ 3 diarrhea was low or zero. In group A, 17 serious ADRs were observed in 10 patients (17%); all improved or recovered. In group B, no serious ADRs were observed. No treatment-related deaths were reported in either group., Conclusions: NK012 monotherapy yielded an RR similar to the RR of irinotecan monotherapy that was reported in the phase III EPIC trial (4.2%), and the incidence of grade ≥ 3 diarrhea was low. Based on the incidence and severity of febrile neutropenia and grade ≥ 3 neutropenia, the initial dose of NK012 28 mg/m2 may be too high for colorectal cancer patients who have previously been treated with an oxaliplatin-based chemotherapy regimen.- Published
- 2018
- Full Text
- View/download PDF